产品说明书

Desonide

Print
Chemical Structure| 638-94-8 同义名 : Budesonide acetonide
CAS号 : 638-94-8
货号 : A294822
分子式 : C24H32O6
纯度 : 98%
分子量 : 416.507
MDL号 : MFCD00866151
存储条件:

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(252.1 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:

2% DMSO+49% PEG 300+dd water 10 mg/mL

生物活性
描述 Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses[3]. Desonide topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions (eg, atopic dermatitis). Desonide showed depigmenting properties in women with axillary hyperpigmentation. It induced significant colorimetric improvement compared with placebo.[4]. The in vitro skin permeation showed that desonide reached the site of action of the topical corticosteroids, from both formulations (57.8 and 51.7 µg/cm2); however, the desonide amount retained in the dermis was lower with D-GC (gel-cream developed)[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01935310 Photoaging Not Applicable Completed - Colombia ... 展开 >> Centro de servicios CES Sabaneta Medellín, Antioquia, Colombia, 050021 收起 <<
NCT03758365 Vasoconstriction Phase 1 Recruiting January 15, 2019 France ... 展开 >> CPCAD Recruiting Nice, France, 06200 Contact: Catherine Queille-Roussel, MD 收起 <<
NCT02732314 Dermatitis, Atopic ... 展开 >> Eczema 收起 << Phase 4 Completed - United States, North Carolina ... 展开 >> Wake Research Associates, LLC Raleigh, North Carolina, United States, 27612 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.00mL

2.40mL

1.20mL

24.01mL

4.80mL

2.40mL

参考文献

[1]Kahanek N, Gelbard C, Hebert A. Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs. 2008 Jul;17(7):1097-104.

[2]Bhankharia DA, Sanjana PH. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study. Indian J Dermatol Venereol Leprol. 2004 Sep-Oct;70(5):288-91.

[3]Kahanek N, Gelbard C, Hebert A. Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs. 2008 Jul;17(7):1097-104

[4]Castanedo-Cazares JP, Lárraga-Piñones G, Ehnis-Pérez A, Fuentes-Ahumada C, Oros-Ovalle C, Smoller BR, Torres-Álvarez B. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013;6:29-36

[5]Rosa P, Santos JD, Lehmen TF, Weber J, Flores FC, Silva CB, Oliveira SM, Brusco I, Milani GB, Adams AI. In vitro and in vivo evaluation of a desonide gel-cream photostabilized with benzophenone-3. Drug Dev Ind Pharm. 2016 Jan;42(1):19-27